Octapharma USA announces FDA approval of cutaquig 16
July 26, 2021
Octapharma USA today announced the U.S. Food & Drug Administration (FDA) has approved cutaquig® for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig® for adults with PI. “The FDA approval provides physicians and families with more treatment options for …